2025 was Novo Nordisk’s worst year in over three decades. The stock fell minus 54% from its peak — and is now trading at a PE of 11.5x, against a historical median of 30x. At the same time, the company received FDA approval in December 2025 for the Wegovy pill — the world’s first oral GLP-1 weight-loss medication. A schizophrenic situation.
This is Pharma #01 in my new series. I am looking at NVO systematically: what went wrong in 2025, what the Wegovy pill changes, how the valuation compares historically, and what Q1 2026 earnings on May 6 must deliver.
1. The 2025 Worst Case — Three Factors Hit Simultaneously
The 54% price decline was not one event, but the convergence of three negative factors in 2025:
Factor 1: Eli Lilly Takes the GLP-1 Crown
Eli Lilly’s Zepbound (tirzepatide) outperformed Wegovy (semaglutide) in clinical head-to-head data on both weight loss and cardiovascular outcomes. That shifted the market’s narrative from “Novo Nordisk dominates GLP-1” to “Eli Lilly is taking over.” Investor confidence cracked.
Factor 2: Compounding Threat + Price Pressure
Patent expirations in key markets (Brazil, Canada, China) opened the door for compounding pharmacies offering cheaper semaglutide alternatives. Simultaneously, US government negotiations with Medicare/Medicaid created pricing pressure fears. Both factors compressed near-term revenue expectations significantly.
Factor 3: Valuation De-Rating from 40x to 11x
Growth momentum slows → the premium valuation compresses. A company that was priced at 40x earnings because of explosive growth gets de-rated to 11x when growth slows and competition intensifies. The math is brutal: even if earnings stay flat, multiple compression alone accounts for most of the price decline.
2. Wegovy Pill — The Counter-Catalyst
In December 2025, the FDA approved oral semaglutide in a higher-dose formulation for weight management — the world’s first oral GLP-1 medication for obesity.
Why does this matter?
- Clinical efficacy: 16.6% body weight reduction in trials — beating Eli Lilly’s oral GLP-1 (orforglipron) at 12.4%
- Market expansion: Millions of patients who avoid or cannot tolerate injections can now be addressed
- Competitive moat: Novo Nordisk has years of experience with oral semaglutide manufacturing (Rybelsus for diabetes), giving it a production head start
3. Valuation: PE 11.5x vs. Historical Median 30x
The valuation picture is objectively striking:
- Forward PE today: ~11.5x — at the crash low
- Historical 10-year median PE: ~30x — when Novo Nordisk was a steady compounder
- Discount: ~62% below the historical average
Is this justified? Two scenarios:
Bear case: Eli Lilly permanently dominates, compounding erodes margins, US pricing reform materializes → PE re-rates to 15–18x as a mature pharma with lower growth. Even at 15x, current prices are roughly fair.
Bull case: Wegovy pill opens a new market, GLP-1 global demand doubles, Novo Nordisk regains co-leadership → PE re-rates back toward 25–30x over 3–5 years. That implies 2–3x from current levels.
The market is pricing the bear case. The Wegovy pill data argues for the bull case. The question is: which scenario do you believe over a 3–5 year horizon?
4. Quality Indicators: ROE 53% and 8-Year Dividend Streak
Even in a down year, Novo Nordisk’s quality metrics remain exceptional:
- ROE 53%: Among the highest in global pharma. This reflects pricing power, patent-protected products, and efficient capital allocation. Only companies with genuine moats sustain ROE above 40%.
- 8-year dividend streak: Novo Nordisk has increased its dividend every year for 8 consecutive years — through market cycles, pipeline setbacks, and now the 2025 crash.
- Net cash position: No significant debt concerns — the company funds R&D from cash flow, not debt.
5. Q1 2026 Preview — May 6 Earnings
Novo Nordisk reports Q1 2026 on May 6, 2026. Key data points to watch:
- Wegovy volume growth: How fast is the injectable version growing, and are there early read-throughs on the pill launch?
- US pricing commentary: Has the Medicare/Medicaid pricing pressure materialized? What is the realized price per unit vs. expectations?
- Ozempic (diabetes) volume: Stable base business — any supply disruption or demand softening would be a warning.
- 2026 guidance: Does management maintain or revise its full-year outlook? Guidance cut = negative; guidance hold or raise = stabilization signal.
6. Decision Framework — Buy, Hold or Avoid?
- BUY IF: You have a 3–5 year horizon, believe GLP-1 market grows faster than bears expect, and can tolerate further near-term volatility
- HOLD IF: Already positioned at higher prices — thesis intact (Wegovy pill, quality business, PE compressed). Add on weakness.
- AVOID IF: You need near-term catalysts, cannot stomach -30% more downside scenarios, or believe Eli Lilly dominates permanently and PE compresses further to 8–10x.
The series continues with Pharma #02 (Bayer) and Pharma #03 (Pfizer) — both at distressed valuations with different risk profiles. Novo Nordisk stays in my watchlist with a small initial position building thesis.
7. The GLP-1 Market Landscape — Size and Growth Trajectory
To understand the opportunity (and the risk) in Novo Nordisk, you need to understand the GLP-1 market dynamics. GLP-1 (glucagon-like peptide-1) receptor agonists were originally diabetes drugs that turned out to also produce significant weight loss. This discovery has created one of the fastest-growing pharmaceutical categories in history.
Current market estimates suggest the global GLP-1 market could reach $130–150 billion annually by 2030 — compared to roughly $40 billion in 2024. Novo Nordisk and Eli Lilly together control more than 90% of this market today. No other company is currently close to commercializing a competitive GLP-1 product in the US or EU.
For a dividend growth investor, NVO is interesting not because of its current yield (under 2%) but because of its dividend growth trajectory. If the company can grow dividends 10-15% annually over the next 10 years — which it has done over the past decade — buying at today's compressed valuation could deliver a very attractive yield on cost. That is the investment thesis: not yield today, but yield in 10 years.
8. Pipeline Beyond GLP-1 — What Comes Next
Novo Nordisk is not a one-product company. Its pipeline includes candidates that go well beyond GLP-1:
- CagriSema: A combination of semaglutide and cagrilintide targeting 25%+ weight loss — potentially the most powerful obesity drug in development. Phase 3 results expected in 2026.
- Mim8 (haemophilia): A non-factor therapy for haemophilia A that could capture significant market share in a segment currently dominated by expensive factor treatments.
- Rare endocrine diseases: Multiple early-to-mid stage candidates targeting underserved rare diseases where Novo Nordisk's hormonal biology expertise gives it a competitive advantage.
- Cardiovascular: Semaglutide already has proven cardiovascular outcome data (SELECT trial showed 20% reduction in major cardiovascular events). This opens the cardiology prescribing base, not just endocrinology.
The pipeline depth means Novo Nordisk is not purely dependent on the current GLP-1 commercial products. Even if Eli Lilly dominates the pure obesity market, Novo Nordisk has adjacent opportunities in rare disease, cardiovascular, and haemophilia.
9. Competitive Moat Assessment — How Durable Is It?
The bear case argues the moat is eroding. Here is the honest assessment:
Moat Pillar 1: Manufacturing Scale (Durable)
GLP-1 manufacturing is biologically complex and requires specialized fermentation infrastructure. Novo Nordisk has been building this capacity for decades — its Plainsboro, New Jersey and Kalundborg, Denmark facilities represent billions in irreplaceable infrastructure. New entrants face 5–10 year lead times just to build comparable capacity.
Moat Pillar 2: Clinical Data Package (Durable)
Semaglutide has more published clinical trial data than any other GLP-1 molecule. The cardiovascular outcome data, the long-term safety data, the efficacy data across populations — all of this took 15 years and billions of dollars to generate. It cannot be replicated quickly by a generic or a competitor without going through the same clinical process.
Moat Pillar 3: Prescriber Relationships (Partially Eroding)
Novo Nordisk has deep relationships with endocrinologists worldwide built over decades of diabetes product leadership. However, Eli Lilly's aggressive commercial execution with Zepbound has been chipping away at this, particularly with newer prescribers in primary care who have less historical brand loyalty.
10. Pharma Sector Comparison — NVO vs. Peers
| Company | Forward PE | Yield | ROE | Dividend Streak |
|---|---|---|---|---|
| Novo Nordisk (NVO) | ~11.5x | 1.9% | 53% | 8 years |
| Eli Lilly (LLY) | ~38x | 0.6% | high | 10+ years |
| Johnson & Johnson (JNJ) | ~14x | 3.3% | medium | 60+ years |
| AbbVie (ABBV) | ~16x | 3.8% | high | 12+ years |
Approximate figures as of Q2 2026. Not financial advice. All valuations change daily.
The table illustrates the current NVO anomaly: at 11.5x PE vs. Eli Lilly's 38x, Novo Nordisk trades at a 70% discount to its most direct peer — despite competing in the same GLP-1 market with arguably superior oral medication efficacy data. The market is applying a maximum pessimism discount. That kind of divergence is historically a mean-reversion setup — but only if the underlying business thesis holds.
Calculate Your Own Returns
YOC, Dividend Snowball, Cashflow & Financial Freedom — all calculators free and ready to use.
YOC Calculator → All Calculators →Disclaimer:This article is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All information provided without guarantee. Act on your own responsibility. Full disclaimer →
Related Analyses
Independent hard-asset investor since 2022. Covers dividends from shipping, mining, energy & pipelines from a real private-investor portfolio — with disclosed positions on every analysis.
